Results 101 to 110 of about 11,732 (171)

A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer

Cancer Immunology, Immunotherapy
Salmonella-IL2 is an attenuated Salmonella Typhimurium strain carrying the human gene for IL-2. When orally administered in preclinical trials, the bacterium colonizes tumors and locally releases IL-2, triggering immunologically-mediated tumor cell ...
Gerald Batist, Petr Kavan, Lance Augustin, Janet Schottel, Jordan Moradian, James T. Lee, Daniel Saltzman   +6 more
doaj   +1 more source

FOLFIRINOX optimization through PKPD modelling in pancreatic cancer

, 2020
L’adénocarcinome pancréatique (PDAC) est un problème majeur de santé publique, avec un taux de survie à 5 ans de seulement 9 %. Actuellement, le protocole FOLFIRINOX est le traitementle plus efficace dans le PDAC.
Deyme, Laure
core  

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer Management and Research, 2017
Fadi Braiteh,1 Manish B Patel,2 Monika Parisi,2 Quanhong Ni,2 Siyeon Park,2,3 Claudio Faria2 1Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV, 2Celgene Corporation, Summit, NJ, 3The Ohio State University ...
Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C   +5 more
doaj  

Is gemcitabine effective for pancreatic cancer after progression to FOLFIRINOX?

, 2017
489 Background: Cytotoxic chemotherapy with FOLFIRINOX (5-Fluoracil + Irinotecan + Oxaliplatin) is considered the standard treatment for fit patients (pts) with pancreatic adenocarcinoma.
Rafael Caparica Bitton, Jorge Sabbaga, Bruno Melo Fernandes, Paulo Marcelo Hoff   +3 more
core   +1 more source

Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study)

Scientific Reports
This study aimed to provide evidence regarding the treatment of patients with unresectable pancreatic cancer. We conducted a prospective single-arm phase II trial using the FOLFIRINOX regimen.
Noritoshi Kobayashi, Yasuhiro Yabushita, Ryutaro Mori, Tomoaki Takahashi, Kentaro Miyake, Yu Sawada, Yuki Homma, Ryusei Matsuyama, Naoki Okubo, Eriko Katsuta, Kensuke Kubota, Shoji Yamanaka, Yasushi Ichikawa, Itaru Endo   +13 more
doaj   +1 more source

Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019-2024. [PDF]

Front Oncol
Fuldeore R, Tan CJ, Kimura T, Farrokhi P, Yang R, Willis C, Asche C, Stenehjem D.   +7 more
europepmc   +1 more source

Stage-Specific Prognostic Impact of Longitudinal Body Composition Changes in Patients with Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX: A Dual-Cohort Study. [PDF]

J Clin Med
Demirel A, İnceöz B, Güren AK, Paçacı B, Kocaaslan E, Tunç MA, Akagündüz F, Kaya E, Çimşit C, Demircan NC, Bayoğlu İV.   +10 more
europepmc   +1 more source

Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiotherapy for Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Gupta S, Sarangi S, Jaiswal A, Lattoo MR, Rajpurohit S, Mittal D, Lamin JCA, Durga T, Yadav R, Ahmad Y.   +9 more
europepmc   +1 more source

Real-world feasibility and safety of neoadjuvant FOLFIRINOX in pancreatic ductal adenocarcinoma: a retrospective single-center study. [PDF]

J Gastrointest Oncol
D'Haens S, Billiet A, Topal H, Topal B, Van Herpe F, Dekervel J.   +5 more
europepmc   +1 more source

Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence. [PDF]

NPJ Precis Oncol
Cole S, Campitelli P, Grieb B, Astsaturov I, Von Hoff D, Singh H, Pishvaian MJ, Bekaii-Saab TS, Hosein PJ, Philip PA, Helmstetter A, Maney T, Ribeiro JR, Hamrick J, Magee D, Spetzler D.   +15 more
europepmc   +1 more source